Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Saxenda"

4 News Found

Biocon signs supply deal with Medix for commercialization of generic Saxenda in Mexico
Supply Chain | May 14, 2024

Biocon signs supply deal with Medix for commercialization of generic Saxenda in Mexico

Biocon launches GLP -1, Liraglutide, in UK
News | March 01, 2025

Biocon launches GLP -1, Liraglutide, in UK

The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K.

Biocon's European partner Zentiva receives approval from UK MHRA for Liraglutide
Drug Approval | April 01, 2024

Biocon's European partner Zentiva receives approval from UK MHRA for Liraglutide

The company had earlier announced about the approval received from the MHRA for Liraglutide

High demand leaves Ozempic compensating for Wegovy’s supply shortage: GlobalData
News | December 07, 2022

High demand leaves Ozempic compensating for Wegovy’s supply shortage: GlobalData

Latest Stories

Eight Roads Ventures to host fourth edition of Scale-Up Health conference on Sept 10

Indoco Remedies receives final USFDA approval for rivaroxaban tablets

Senores Pharmaceuticals acquires ANDAs from Teva Pharmaceuticals USA

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries

Packaging